Cytoreductive Cystectomy After EV-302: How We Got Here скачать в хорошем качестве

Cytoreductive Cystectomy After EV-302: How We Got Here

In this video series, Dr. Daniel Roberson of Mayo Clinic, Dr. Abhinav Khanna of Mayo Clinic, and Dr. Nitin Yerram of Hackensack Meridian Health explore the emerging role of cytoreductive cystectomy in the post–EV-302 era, highlighting how improved systemic therapy responses have created new surgical candidates. Together, they examine patient selection, the potential to pause systemic therapy, perioperative outcomes with robotic and open approaches, and the discordance between primary and nodal response, setting the stage for future prospective trials. The first segment of this series focuses on outlining how the success of EV-302 has created a new subset of metastatic bladder cancer patients experiencing deep and durable responses, as well as how this has revived the question of cytoreductive cystectomy, emphasizing patient selection, surgical candidacy, and the potential—but still unproven—benefits of consolidative surgery in this evolving landscape.